This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: ABX EGO VRTX FSLR LNKD

True Blue (TBI) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $16 price target. Company is leveraged to rising ISM new orders index and could see more demand following Hurricane Sandy.

Vertex Pharmaceuticals (VRTX - Get Report) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $43 price target. Have a more cautious outlook for the company's cystic fibrosis portfolio.

Watson Pharmaceuticals (WPI) upgraded at Piper from Neutral to Overweight, Piper Jaffray said. $103 price target. Company offers growth at a reasonable price.

STOCK COMMENTS / EPS CHANGES

LinkedIn (LNKD - Get Report) numbers boosted at Citi. Shares of LNKD now seen reaching $135, according to Citigroup. Estimates also upped, as the company is gaining market share. Buy rating.

Priceline.com (PCLN) numbers raised at Goldman. Shares of PCLN now seen reaching $770, according to Goldman Sachs. Estimates also increased, as the company is realizing higher bookings growth. Buy rating.

Pfizer (PFE) estimates, target reduced at BMO. PFE estimates were cut through 2013, BMO Capital said. Company is being hurt by the stronger dollar. Outperform rating and new $29 price target.

Starbucks (SBUX) estimates, target raised at BofA/Merrill. Shares of SBUX now seen reaching $60, according to Bank of America/Merrill Lynch. Estimates also increased, as new products are driving growth. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABX $13.33 4.10%
EGO $5.02 5.00%
FSLR $63.57 1.00%
LNKD $257.44 -1.10%
VRTX $125.40 -1.90%

Markets

DOW 18,110.14 +72.17 0.40%
S&P 500 2,114.76 +5.84 0.28%
NASDAQ 5,055.4220 -4.8240 -0.10%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs